- Dec 5, 2013
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
IFM2013-04 NCT01971658: Phase 3: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone...
208
- Dec 12, 2012
NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
The ENDEAVOR Trial KD Vs Vd The primary objective of this study was to compare progression-free survival in patients with multiple...
455
- Dec 8, 2012
NCT01592370: Phase 1/2: Safety and Effectiveness of Nivolumab and Daratumumab in Multiple Myeloma
NCT01592370: Phase 1/2: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in...
94
- Dec 9, 2011
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
MMRF CoMMpass Study Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) The primary...
790
- Dec 7, 2011
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
EMN European Myeloma Network NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma...
67
- Dec 18, 2010
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
ELOQUENT - 2 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple...
96